Sorafenib (Nexavar) for Cancer Treatment
An oral targeted therapy for liver, kidney, and thyroid cancer โ blocking VEGFR and RAF pathways to slow tumour growth.
What is Sorafenib?
What it targets
VEGFR and RAF kinase pathways that drive both tumour cell growth and the blood vessel formation tumours need to survive.
Who it may help
Patients with hepatocellular carcinoma, advanced renal cell carcinoma, or radioactive iodine-refractory differentiated thyroid cancer.
Why testing matters
Liver function, blood pressure, and thyroid function tests are required before starting; no specific biomarker test is needed.
Which cancers can Sorafenib treat?
| Hepatocellular carcinoma (HCC) | Approved for unresectable HCC โ the most common form of primary liver cancer. Used when surgery, ablation, or other local curative treatments are not suitable. Sorafenib was the first systemic agent to demonstrate survival benefit in advanced HCC (SHARP trial) and remained the standard first-line option for many years before newer immunotherapy-based combinations emerged. |
| Renal cell carcinoma (RCC) | Approved for advanced RCC in selected patients. Sorafenib was among the first targeted agents approved for this indication, particularly for patients after prior cytokine therapy. Newer agents including cabozantinib, sunitinib, and immunotherapy combinations have emerged, but sorafenib remains relevant in specific clinical settings. |
| Differentiated thyroid cancer (DTC) | Approved for locally recurrent or metastatic, progressive DTC that no longer responds to radioactive iodine (RAI-refractory). It is one of few approved systemic options for this specific setting. Lenvatinib is also approved in this space and is generally preferred in current guidelines, but sorafenib retains an established role. |
| Other cancers (investigational) | Sorafenib has been studied in other tumour types including acute myeloid leukaemia (AML with FLT3 mutations), desmoid tumours, and hepatocellular carcinoma combination strategies. These uses are not routine and should be considered only within a clinical trial or with specialist oncology guidance. |
Who may be eligible for Sorafenib?
- Confirmed diagnosis of unresectable HCC, advanced RCC, or RAI-refractory progressive DTC
- HCC patients: adequate liver function (Child-Pugh A or selected Child-Pugh B)
- Adequate kidney function โ assessed by serum creatinine and eGFR before starting
- ECOG performance status 0โ2 โ ability to perform self-care and daily activities
- Blood pressure controlled before starting โ sorafenib can worsen hypertension
- No active uncontrolled bleeding or recent major haemorrhage
- No planned surgery in the immediate near-term โ sorafenib must be held before operations
- Not pregnant or breastfeeding โ sorafenib causes foetal harm; effective contraception required
- Careful review of concurrent medicines for interactions before starting
How does Sorafenib work?
- Blocking tumour blood-vessel signals (anti-angiogenesis)
- Blocking RAF kinase โ cancer cell proliferation
- Blocking additional kinase targets
- Slowing progression rather than curing
Tests needed before starting Sorafenib
| Biopsy and histopathology | Confirms cancer type and is essential for selecting the correct treatment and planning monitoring. |
| CT, MRI, or PET-CT imaging | Measures disease extent and creates a baseline for response assessment at future scans. |
| Liver function tests (LFTs) | Especially important in HCC and patients with cirrhosis โ helps determine Child-Pugh score and sorafenib suitability. |
| Kidney function tests | Serum creatinine, BUN, and eGFR checked before starting โ sorafenib requires adequate renal function. |
| Complete blood count (CBC) | Baseline haemoglobin, white cell count, and platelets checked before treatment begins. |
| Blood pressure measurement | Sorafenib commonly raises blood pressure โ BP must be measured and controlled before and during therapy. |
| Thyroid function tests | Relevant for thyroid cancer patients and for monitoring long-term sorafenib-related thyroid changes. |
| Medication and supplement review | Full review of current medicines, supplements, and herbal products to identify interactions before starting. |
How is Sorafenib given?
| Route of administration | Oral tablets โ taken by mouth at home, no infusion or hospital visit needed for dosing. |
| Standard adult dose | 400 mg (two 200 mg tablets) twice daily โ total 800 mg per day, as prescribed by the oncologist. |
| When to take it | Without food: at least 1 hour before a meal or 2 hours after a meal, with a full glass of water. |
| Dose reduction | If side effects occur, your oncologist may reduce to 400 mg once daily or 400 mg every other day. |
| Missed dose | Skip the missed dose if it is close to the next scheduled dose โ do not take two doses at once. |
| Duration of treatment | Continue as long as there is clinical benefit and side effects are manageable โ decided by your oncologist. |
| Before surgery | Sorafenib must be held before and after surgical procedures โ discuss the timing with your surgeon and oncologist. |
Possible benefits of Sorafenib
| Slowing cancer progression | Sorafenib has demonstrated prolonged progression-free survival compared to placebo in HCC (SHARP trial), RCC, and RAI-refractory DTC โ the primary goal in advanced disease. |
| Oral convenience | Taken as tablets at home with no need for regular hospital infusions โ allowing patients to maintain more normal daily routines. |
| Anti-angiogenic effect | By cutting off the tumour's blood supply through VEGFR blockade, sorafenib can limit the tumour's ability to expand and spread locally. |
| Disease stabilisation | Many patients achieve stable disease โ where the tumour neither shrinks dramatically nor grows significantly โ which can be a meaningful benefit in the context of advanced cancer. |
| Broad multi-cancer use | One of few oral targeted therapies with established roles across three distinct cancer types: liver, kidney, and thyroid cancer. |
| Generic availability | Wide generic availability in markets like India helps reduce the cost burden compared to many newer targeted therapies. |
Side effects of Sorafenib
Side effects vary between patients. Some are manageable with dose adjustments and supportive care. Contact your oncologist promptly for any urgent symptoms.
| Hand-foot skin reaction (HFSR) | Pain, redness, blistering, or peeling on palms and soles โ the most distinctive side effect of sorafenib. Manageable with moisturising creams, padding, and dose adjustment. |
| Diarrhea | Loose or frequent stools โ may require anti-diarrhoeal medicines, hydration support, and dose modification if severe. |
| Fatigue | Tiredness and reduced stamina are common and can affect daily activities. Rest, pacing activities, and addressing anaemia or other contributing causes can help. |
| High blood pressure (hypertension) | Sorafenib commonly raises blood pressure โ regular monitoring is required and antihypertensive medicines may be needed. |
| Skin rash and dryness | Redness, itching, flaking, or generalised rash may occur โ emollients and topical treatments can help. |
| Nausea and reduced appetite | Common in the early weeks of treatment โ anti-nausea medicines and dietary adjustments may ease symptoms. |
| Hair thinning or alopecia | Hair may thin gradually during treatment โ this usually does not cause complete hair loss but can be distressing. |
| Mouth sores (mucositis) | Painful sores inside the mouth โ gentle oral hygiene and specific mouthwashes recommended by your care team. |
| Weight loss | Reduced appetite and gastrointestinal side effects can contribute to unintended weight loss โ nutritional support may be needed. |
| Elevated liver enzymes | Sorafenib can affect liver function โ especially important in HCC patients who often already have underlying liver disease. |
Call your doctor urgently if you develop:
- Chest pain, tightness, or palpitations โ may indicate a cardiac event
- Severe shortness of breath or sudden confusion
- Coughing or vomiting blood, or black tarry stools โ indicates serious bleeding
- Severe abdominal pain that comes on suddenly
- Very high blood pressure reading โ above 180/110 mmHg
- Yellowing of the eyes or skin, or very dark urine โ liver warning signs
- Severe blistering, peeling, or open sores on hands or feet
- High fever with skin redness or widespread rash
Important precautions and warnings
- Tell your oncologist about all current medicines โ sorafenib interacts with blood thinners, anticonvulsants, and some antibiotics
- Blood pressure must be controlled before and monitored closely throughout treatment
- Patients with cirrhosis or existing liver disease need careful liver function monitoring during treatment
- Sorafenib must be stopped before surgery and not restarted until wounds have healed
- Effective contraception required for women during treatment and for 6 months after the last dose
- Male patients should also use contraception during treatment to avoid foetal exposure
- Do not breastfeed during sorafenib treatment โ drug may pass into breast milk
- Inform your dentist or any surgeon you are taking sorafenib before any procedure
- Avoid grapefruit and grapefruit juice during sorafenib treatment
- Herbal supplements and over-the-counter products should be discussed with your oncologist before use
Sorafenib in combination treatment
Sorafenib is most commonly used as a single agent in its approved indications, but it has been studied in combination approaches.
| HCC โ sorafenib after TACE | Sorafenib has been evaluated alongside transarterial chemoembolisation (TACE) in liver cancer. Current evidence does not consistently support combination use โ it is generally used as a systemic option when local treatments are no longer suitable. |
| HCC โ sorafenib vs immunotherapy | Newer first-line options in advanced HCC include atezolizumab plus bevacizumab and tremelimumab plus durvalumab. Sorafenib may still be appropriate for patients with contraindications to these newer regimens โ your oncologist will advise. |
| RCC โ treatment sequencing | In kidney cancer, sorafenib may be used in patients who have progressed on or are not suitable for first-line immunotherapy or sunitinib-based therapy โ sequencing depends on prior treatment and current performance status. |
| DTC โ sorafenib vs lenvatinib | In RAI-refractory differentiated thyroid cancer, both sorafenib and lenvatinib are approved options. Lenvatinib is generally preferred in current guidelines, but sorafenib may be chosen based on tolerability, cost, and access. |
If Sorafenib stops working
Resistance to sorafenib can develop over time. There are steps your oncology team can take to confirm progression and plan next-line treatment.
| Confirm progression with imaging | Repeat CT or MRI to confirm that the cancer has grown โ radiological progression must be verified before changing treatment. |
| Review adherence and tolerability | Dose reductions or interruptions may have reduced drug exposure. Your oncologist will assess whether dose was adequate and well-tolerated. |
| Liver cancer โ second-line options | Approved second-line options after sorafenib in HCC include regorafenib (for patients who tolerated sorafenib), cabozantinib, and ramucirumab (for patients with elevated AFP). Immunotherapy combinations may also be considered. |
| Kidney cancer โ next-line therapy | Multiple second-line options exist for RCC, including cabozantinib, axitinib, nivolumab, and everolimus โ choice depends on prior therapies and current guidelines. |
| Thyroid cancer โ alternative systemic therapy | In RAI-refractory DTC that has progressed on sorafenib, lenvatinib, cabozantinib, and other kinase inhibitors may be options. RET and NTRK testing can identify targetable alterations in some patients. |
| Molecular testing | NGS-based testing or liquid biopsy may identify actionable mutations in resistant disease โ relevant especially for thyroid cancer where RET, NTRK, and BRAF alterations have targeted options. |
| Clinical trial evaluation | Trial participation should be discussed after sorafenib failure โ especially for patients with no clear approved next-line option or those with rare histologies. |
Cost of Sorafenib
Sorafenib cost depends on country, brand versus generic, insurance coverage, dose, duration, and local hospital pricing.
| Branded Nexavar | Branded sorafenib (Nexavar) is significantly more expensive than generics and costs vary widely by country and healthcare system. |
| Generic sorafenib in India | India has multiple generic manufacturers of sorafenib following the landmark compulsory licence granted in 2012. Generics are substantially more affordable and widely available through oncology pharmacies and hospitals. |
| Cost in China | Sorafenib is available in China under NMPA approval. Prices vary depending on whether it is procured through hospital formulary, insurance, or private sourcing. Generic options may also be available. |
| Insurance and reimbursement | Coverage varies significantly by country and insurance plan. Patients in India may access sorafenib through CGHS, state government cancer schemes, or institutional pricing. Ask your hospital about available patient assistance or reimbursement pathways. |
| Monitoring costs | Total treatment cost must account for regular liver function tests, CBC, blood pressure monitoring, imaging, and supportive medicines for side effect management. |
Where is Sorafenib available?
India
Generic sorafenib is widely available from multiple manufacturers across India, making it among the most accessible targeted cancer drugs in the country. Available through oncology pharmacies, government hospitals, and private cancer centres.
China
NMPA approved for HCC, RCC, and differentiated thyroid cancer. Available through leading cancer hospitals in Beijing, Shanghai, Guangzhou, and other major cities. Insurance coverage varies.
USA
FDA approved for HCC, RCC, and RAI-refractory DTC. Available as branded Nexavar with generic options. Coverage depends on insurance plan.
Europe
EMA approved for HCC, RCC, and DTC. Available in most European countries through hospital oncology formularies and national health services.
Southeast Asia
Available in Thailand, Singapore, Malaysia, and other countries โ primarily through specialist cancer hospitals and oncology centres. Generic access varies by country.
Clinical trials involving Sorafenib
Sorafenib continues to be studied in combinations, sequencing strategies, and resistant or special-population settings.
| HCC โ immunotherapy combinations | Trials evaluating sorafenib in combination with or sequenced after checkpoint inhibitors in liver cancer โ particularly in patients not eligible for newer first-line regimens. |
| HCC โ sorafenib after local therapy | Studies examining sorafenib as systemic consolidation after TACE, ablation, or resection in high-risk liver cancer patients. |
| AML โ FLT3-mutated disease | Sorafenib targets FLT3 and has been studied in FLT3-mutated AML, particularly in combination with standard chemotherapy and as maintenance after transplant. |
| RCC โ sequencing and biomarker studies | Research on identifying which patients benefit most from sorafenib in the current era of immunotherapy-dominant first-line treatment for kidney cancer. |
| DTC โ combination with radioactive iodine | Studies evaluating whether sorafenib and similar agents can re-sensitise tumours to radioactive iodine in patients with DTC through MAPK pathway inhibition (redifferentiation). |
Your treatment journey with Sorafenib
Diagnosis and staging
Review of local and curative options
Baseline assessment before starting
Starting sorafenib at 400 mg twice daily
Early monitoring โ first 4 to 8 weeks
Response assessment at 6 to 8 weeks
Long-term maintenance and monitoring
Planning next steps if sorafenib stops working
Questions to ask your oncologist about Sorafenib
- Is sorafenib the right first choice for my cancer type and stage?
- What is the realistic goal of sorafenib in my case?
- How should I take the tablets and does timing with food matter?
- What side effects should I report to you urgently?
- How often will I need blood tests, imaging, and blood pressure checks?
- Can the dose be reduced if side effects become too difficult to manage?
- Is generic sorafenib available and as effective as Nexavar?
- What are my next-line options if sorafenib stops working?
How CancerFax supports Sorafenib patients
CancerFax helps patients navigate access to sorafenib and connect with oncologists experienced in liver, kidney, and thyroid cancer treatment.
| Medical report review | Upload your imaging, biopsy, blood tests, and prior treatment records โ our team will review them and explain what they mean for sorafenib eligibility and your treatment plan. |
| Specialist connection | We connect patients with oncologists and hepatologists experienced in HCC, RCC, and thyroid cancer targeted therapy in India, China, Singapore, South Korea, and other treatment destinations. |
| Second opinion | If you are uncertain whether sorafenib is the right choice, or if it has stopped working, CancerFax arranges specialist second opinions โ including from Chinese centres known for liver cancer and cell therapy expertise. |
| Drug access and generic sourcing | We help patients check practical generic sorafenib availability in India and access options in China and other countries where cost or procurement is a concern. |
| Clinical trial matching | For patients who have progressed on sorafenib or want to explore newer options, CancerFax evaluates clinical trial eligibility across registered programmes in India, China, and internationally. |
| International care coordination | For patients considering treatment at a specialist cancer centre abroad, CancerFax manages hospital coordination, visa and travel support, medical translation, and post-treatment follow-up. |
Frequently asked questions about Sorafenib
Common questions from patients and caregivers
Sorafenib is a targeted therapy, not chemotherapy. It works by blocking specific kinase signals โ including RAF and VEGFR pathways โ that cancer cells use to grow and form new blood vessels. Chemotherapy attacks all rapidly dividing cells throughout the body. Sorafenib is taken as an oral tablet and is designed to slow or stop cancer progression in selected tumour types rather than broadly killing cells.
Response to sorafenib is usually assessed through imaging (CT or MRI) after 6 to 8 weeks of treatment. In many patients, the first goal is disease stabilisation rather than tumour shrinkage. Your oncologist will monitor your response and decide whether to continue, adjust the dose, or consider alternative options based on your scan results, blood tests, and tolerance.
Sorafenib should be taken without food โ at least one hour before or two hours after a meal, with a glass of water. Avoid grapefruit and grapefruit juice, as it may interfere with drug metabolism. Tell your oncologist about all medicines, supplements, and herbal products you are taking, as sorafenib has interactions with several commonly used drugs including blood thinners, anticonvulsants, and certain antibiotics.
Yes. Sorafenib is available as generic versions in several countries, including India, where it has an important history linked to the country's first compulsory licence for a cancer drug. Generic sorafenib contains the same active ingredient at the same dose and has been used widely. Ask your oncologist or pharmacist about generic availability and legitimate sourcing in your country. CancerFax can also help with access guidance across India, China, and other regions.
Hand-foot skin reaction (HFSR) is one of the most common side effects of sorafenib. It causes pain, redness, swelling, peeling, or blisters on the palms of the hands and soles of the feet. It can be managed with dose reduction, urea-based moisturising creams, avoiding pressure or friction on affected areas, and wearing cushioned footwear. Tell your oncologist at the first signs โ early management prevents it from becoming severe. Most patients can continue sorafenib with appropriate care.
Do not stop sorafenib without speaking to your oncologist first. Some side effects can be managed with dose reduction or supportive medicines rather than stopping treatment. Stopping abruptly without guidance may affect your cancer treatment outcome. If side effects feel unmanageable, contact your oncology team the same day โ they can advise whether a break, dose reduction, or additional medicines are needed.
If your cancer progresses on sorafenib, your oncologist will review imaging, blood tests, and your overall condition to confirm progression. Depending on your cancer type, there are approved second-line options โ including newer immunotherapy-based regimens for liver cancer and other agents for kidney and thyroid cancer. Molecular testing or a liquid biopsy may also be considered. CancerFax can help arrange a second opinion or explore clinical trial options if standard next-line treatment is not available locally.
No. Sorafenib can cause serious harm to an unborn baby. Women of childbearing age must use effective contraception during treatment and for at least six months after the last dose. Sorafenib should not be used during breastfeeding. If you are pregnant, planning to become pregnant, or breastfeeding, discuss this with your oncologist before starting treatment. Male patients should also use contraception during treatment.